IAP12 Rec'd PCT/PTO 0.5 NOV 2007

FORM PTO-1390 (REV. 01-2003)

US DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER
127766

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/585,574

•	C	ONCERNING A FILING UND	•						
		TIONAL APPLICATION NO. 5/000051	INTERNATIONAL FILING DATE January 11, 2005	PRIORITY DATE CLAIMED January 27, 2004					
TITLE OF INVENTION NEEDLELESS SYRINGE PROVIDED WITH A DAMPING INJECTOR RECEPTACLE									
APPLICANT(S) FOR DO/EO/US Patrick ALEXANDRE; Georges BAUD; Bernard BROUQUIERES; Laurent D'EMMANUELLE; Denis ROLLER									
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:									
1.		This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.							
2.	$\boxtimes$	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.							
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.							
4.		The US has been elected (Article 31).							
5.		A copy of the International Application as filed (35 U.S.C. 371(c)(2))							
		a. $\square$ is attached hereto (required only if not communicated by the International Bureau).							
		b.  has been communicated by the International Bureau.							
		c. $\square$ is not required, as the application was filed in the United States Receiving Office (RO/US).							
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))							
		a.  is attached hereto.							
		b.  has been previously submitted under 35 U.S.C. 154(d)(4).							
		c.	was filed in English.						
7.		Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))							
		a.   are attached hereto (required only if not communicated by the International Bureau).							
		b. have been communicated by the International Bureau.							
		c. $\square$ have not been made; however, the time limit for making such amendments has NOT expired.							
		d.  have not been made and will not be made.							
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).							
10.		An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).							
Items	s 11 t	to 20 below concern document(s) o	or information included:						
11.		An Information Disclosure Statemer	nt under 37 CFR 1.97 and 1.98.						
12.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
13.		A preliminary amendment.							
14.		An Application Data Sheet under 37 CFR 1.76.							
15.		A substitute specification.							
16.		A power of attorney and/or change of address letter.							
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.							
18.		A second copy of the published international application under 35 U.S.C. 154(d)(4).							
19.		A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).							
20.	$\boxtimes$	Other items or information: Notificat	ion of Acceptance and Filing Rece	eipt Status Request.					

\$ 5, 1 1, 50 m

.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) INTERNATIONAL APPLICATION NO. 0/585,574 PCT/FR05/000051			ATTORNEY'S DOCKET NUMBER							
21.  The following fees are	CALCULATIONS PTO USE ONLY									
27. The lonewing ices are	OALOOLATIONO	T TO OOL ONE!								
İ										
BASIC NATIONAL FEE (37 CF	\$									
SEARCH FEE (37 CFR 1.492(t				\$						
(		•								
International preliminary examir										
the USPTO as IPEA or ISA and industrial applicability for all claim										
national phase										
International search fee (37 CF										
ĺ										
International search report prov										
the search fee is paid										
All situations not provided for al	bove	•	\$ 510.00							
EXAMINATION FEE (37 CFR 1	1.492(c)(1)-(2)):			\$						
	(5)(1) (2)			*						
International preliminary examin										
the USPTO as IPEA or ISA and favorable as to novelty, inventive step, and										
industrial applicability for all cla national phase		* *	• 000							
Trational priase	•••••		<b>y 0.00</b>							
All situations not provided for al	All situations not provided for above\$ 210.00									
Surcharge of \$130.00 for furnis	hing the search	fee, the examination fe	e or the oath or	\$						
declaration after the date of cor	mmencement of	the national phase (37	CFR 1.492(h)).							
APPLICATION SIZE FEE	50									
Total pages - 100 =	÷ 50	= †	x 260 =	\$						
tround up to next integer										
CLAIMS N	UMBER FILED	NUMBER EXTRA	RATE	\$						
TOTAL CLAIMS	- 20	=	x 50.00 =	\$						
INDEPENDENT CLAIMS	- 3	=	x 210.00 =	\$						
MULTIPLE DEPENDENT CLAI	\$									
	\$									
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.										
reduced by 72.			SUBTOTAL =	\$						
Processing fee of \$130.00 for fo	urnishing the Eng	olish translation later th		\$						
the earliest claimed priority date	e (37 CFR 1.492	(i)).		•						
	\$									
Fee for recording the enclosed	\$									
accompanied by an appropriate	accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +									
		TOTAL FE	EES ENCLOSED =	\$						
				Amount to be						
				refunded:	\$ \$					
a.	the amount of \$	to cover the abo	ve fees is enclosed	charged:	Ι Φ					
c.  The Commissioner	is hereby author				t any overpayment to					
Deposit Account No	Deposit Account No. <u>15-0461</u> .									
d.  Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.										
illioilliation should	a not be include	ed off titles form. From	de credit card informa	ition and authorization	1011 - 10-2036.					
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b))										
must be filed and granted to restore the application to pending status.										
SEND ALL CORRESPONDENCE TO:										
OLIFF & BERRIDGE, F	Jak.									
Customer Number:	am P. Berridge									
			REGISTRATIO	ON NUMBER: 30,0	-24					
Date November 5, 2007		NAME: Kirk D	D. Berkhimer							
		REGISTRATIO	ON NUMBER: 59,8	74						
1										
1		w j								
I			•							

## PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Patrick ALEXANDRE et al.

ATTN: Mail Stop PCT

Application No.: 10/585,574

Docket No.: 127766

Filed: July 10, 2006

For:

NEEDLELESS SYRINGE PROVIDED WITH A DAMPING INJECTOR

RECEPTACLE

## NOTIFICATION OF ACCEPTANCE AND FILING RECEIPT STATUS REQUEST

100

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The above-captioned patent application entered the National Phase on July 10, 2006. The 35 U.S.C. 371 requirements were completed on July 10, 2006.

The original Notification of Acceptance and Filing Receipt have not yet been received. It is respectfully requested that the original Notification of Acceptance and Filing Receipt be immediately forwarded to the attorneys of record at the address set forth below.

If there are any questions regarding this matter, please contact the undersigned at the telephone number set forth below.

Respectfully submitted,

William P. Berridge Registration No. 30,024

Kirk D. Berkhimer Registration No. 59,874

WPB:KDB/cdk

Date: November 5, 2007

OLIFF & BERRIDGE, PLC P.O. Box 320850 Alexandria, Virginia 22320-4850 Telephone: (703) 836-6400